Contrary to previous research, a new study of female participants finds no link between migraine and the risk of developing Parkinson’s disease. The study was
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
BioMarin is bringing prominent dealmaker James Sabry onto its executive team, along with Amgen rare disease veteran Greg Friberg. Sabry will start on Oct. 7
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Dermatology biotech Timber Pharmaceuticals’ Phase 3 trial investigating its treatment in a rare inherited skin disorder missed all primary and secondary endpoints, the company announced
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
The FDA rejected linvoseltamab, Regeneron’s experimental antibody for multiple myeloma, the company announced Wednesday morning. In an earnings call earlier this … Sign up to
Plus, news about Retension Pharmaceuticals: Vandria tops up Series A with another $10M: The Swiss biotech increased its round total to … Sign up to
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Dr. Reddy’s Laboratories, its CRDMO arm Aurigene and Stanford spinout Kainomyx are teaming up to develop an anti-malarial drug with a new mechanism of action